“I am very excited and honored to join the advisory board of uBiome. I strongly believe that the next frontier in precision therapeutic medicine lies in understanding and harnessing the potential of the human microbiome.” - Dr. Reddy
SAN FRANCISCO (PRWEB) October 17, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Srinivasa Reddy, PhD, a professor in the departments of Medicine, Molecular and Medical Pharmacology, and Obstetrics and Gynecology at University of California Los Angeles, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Reddy will bring to uBiome expertise regarding the connection between the gut and cardiovascular disease. The appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Reddy is at the forefront of emerging science that points to a correlation between gut and heart health,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are thrilled to explore this further with his addition to our board of scientific advisors.”
Dr. Reddy is a professor in-residence in the departments of Medicine, Molecular and Medical Pharmacology, and Obstetrics and Gynecology. He is a member of Molecular Pharmacology Home Area, Molecular, Cellular and Integrative Physiology Home Area, Jonsson Comprehensive Cancer Center, Molecular Biology Institute, Molecular Toxicology Interdepartmental Degree Program, and on faculty in Cardiology. Dr. Reddy’s lab focuses on the metabolites of the gut microenvironment that may be associated with both the hardening or narrowing of the arteries and cardiovascular disease, as well as cancer development and progression.
About joining uBiome's Scientific Advisory Board, Dr. Reddy said, “I am very excited and honored to join the advisory board of uBiome. I strongly believe that the next frontier in precision therapeutic medicine lies in understanding and harnessing the potential of the human microbiome.”
In addition to Dr. Reddy, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.